Avoid. Despite strong founder-led governance (Şahin & Türeci retain ~15% stakes with capped dilution), BioNTech's 30/100 Value Compounder Score reflects clinical-stage pipeline risk and narrow moat—the business remains anchored to mRNA royalties rather than durable competitive advantage. Leadership alignment cannot offset execution uncertainty in oncology and rare disease, where cash burn and low near-term revenue visibility dominate the risk/reward.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for BioNTech SE:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 33/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates BioNTech SE (BNTX) at 33/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. Despite strong founder-led governance (Şahin & Türeci retain ~15% stakes with capped dilution), BioNTech's 30/100 Value Compounder Score reflects clinical-stage pipeline risk and narrow moat—the business remains anchored to m
BNTX's current Stocky Verdict is 33/100, placing it in the "Avoid" band. This composite combines a 30/100 Compounder score, 88/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for BioNTech SE yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
BioNTech SE scores 88/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
BioNTech SE's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to BioNTech SE.
Sign up free and unlock the full analysis on BNTX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
Or jump straight to the interactive dashboard for BNTX in the app.
